ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

CORRECT(12/13): FDA Panel Recommends Use Of Alexza Pharma's Bipolar Treatment

("FDA Panel Recommends Use Of Alexza Pharma's Bipolar Treatment" on Dec. 13 and an earlier story on Jan. 18 misstated that Valeant Pharmaceuticals International Inc. is currently a commercial partner for the drug. A corrected version follows:) DOW JONES NEWSWIRES Alexza Pharmaceuticals Inc. (ALXA) said a U.S. Food and Drug Administration panel has recommended that its schizophrenic and bipolar disorder treatment be approved for use. Shares were recently up 76% to $1.10 as the company's chief executive called the panel's recommendation "another step forward" for the drug's development. Alexza in August said it refiled its new drug application for the treatment, adding new data and sections that aimed to address safety concerns raised by the agency last year. "If approved, we believe Adasuve represents a valuable treatment option for patients and physicians alike. We look forward to continuing to work toward our goal of bringing Adasuve to market in 2012," said Chief Executive Thomas B. King. Alexza last month reported its third-quarter loss widened sharply from a year earlier as it recorded higher research and development expenses and a loss on a contingent liability. -By Mia Lamar, Dow Jones Newswires; 212-416-3207; [email protected]

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
03/24/201703:02:00Valeant Paid CEO $62.7 Million Total -- WSJ
03/23/201718:45:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 4th...
03/23/201714:44:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 3rd...
03/23/201713:51:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 3rd...
03/23/201712:01:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 2nd...
03/23/201711:35:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- Update
03/23/201710:11:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016
03/23/201708:05:22Proxy Statement (definitive) (def 14a)
03/21/201716:51:10Current Report Filing (8-k)
03/21/201716:30:00Valeant Completes Refinancing Transactions
03/21/201716:30:00Valeant Completes Refinancing Transactions
03/20/201721:45:00Valeant Announces the Early Results of Tender Offers for Its...
03/20/201721:45:00Valeant Announces the Early Results of Tender Offers for Its...
03/20/201717:00:00Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma...
03/20/201717:00:00Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma...
03/17/201716:24:22Current Report Filing (8-k)
03/16/201717:13:47Statement of Changes in Beneficial Ownership (4)
03/16/201717:06:04Statement of Changes in Beneficial Ownership (4)
03/16/201716:43:41Statement of Beneficial Ownership (sc 13d)
03/16/201716:32:58Statement of Changes in Beneficial Ownership (4)

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US